What are the functions and effects of tucatinib/tucatinib?

Tucatinib/Tucatinib (Tucatinib) is a new, highly selective HER2 tyrosine kinase inhibitor (HER2-TKI), specially designed for patients with HER2-positive breast cancer. Its main mechanism of action is to precisely block the signaling pathway downstream of the HER2 receptor, thereby inhibiting the proliferation and metastasis of tumor cells. Compared with traditional HER2-targeted drugs, tucatinib is unique in that it barely inhibits EGFR. Therefore, while controlling tumor growth, it significantly reduces common side effects such as rash and gastrointestinal discomfort, embodying the modern targeted therapy concept of "efficient and gentle".

In terms of therapeutic effect, multiple overseas clinical studies have shown that tucatinib, used in combination with trastuzumab and capecitabine, can bring significant survival benefits to patients withHER2-positive metastatic breast cancer, especially for patients with brain metastases, which is a clinical breakthrough. Due to its small molecular structure, tucatinib can penetrate the blood-brain barrier, making it superior in controlling metastatic lesions in the central nervous system. This feature makes it one of the few HER2-targeted drugs currently with "brain metastasis indications."

In addition to breast cancer, tucatinib has also shown potential efficacy inHER2-positive gastric cancer, colorectal cancer and other solid tumors, and relevant clinical studies are ongoing. With the rapid development of precision medicine, HER2 mutations are not only limited to breast cancer, but have also been found in a variety of tumors, providing broader prospects for the application expansion of tucatinib.

From the perspective of drug characteristics, tucatinib is administered orally and has stable metabolism, making it suitable for long-term maintenance treatment. Its main effects include delaying tumor progression, improving brain metastasis control rate, improving quality of life and prolonging overall survival. For patients who have previously used trastuzumab, pertuzumab or T-DM1, tucatinib provides a new treatment option, bringing the treatment of HER2-positive advanced breast cancer into a more refined and stratified era.

Reference materials:https://www.tukysa.com/